Spruce Biosciences Inc SPRB.OQ SPRB.O is expected to show a fall in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Spruce Biosciences Inc is for a loss of $13.93 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Spruce Biosciences Inc is $132.00, about 9.6% above its last closing price of $119.29
This summary was machine generated November 7 at 16:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)